1Monnier L, Lapinski H, Colette C. Contributions of fasting and poslprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care, 2003,26:881- 885.
2Uchino H, Niwa M, Shimizu T, et al. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue. Endocr J, 2000,47:639-641.
3Kishikawa H, Okada Y, Kanda K, et al. Indication for nateglinide in type 2 diabetes mellitus. J UOEH, 2005,27:179-188.
4Horton E, Foley JE, Shen SG, et al. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatmentnaive patients with type 2 diabetes. Curr Med Res Opin, 2004,20:883-889.
5Fonseca V, Grunberger G, Gupta S, et al. Addition of nateglimide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and unproves overall glycemic control. Diabetes Care, 2003,26:1685-1690.
6Del Prato S, Heine RJ, Keilson L, et al. Treatment of patients over 64 years of age with type 2 diabetes experience from nateglinide pooled database retrospective analysis. Diabetes Care, 2003,26:2075-2080.
